BR5402C — Competitive Intelligence Brief

BR5402C (BR5402C) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIF-1α inhibitor. Area: Oncology.

phase 2 HIF-1α inhibitor HIF-1α Oncology Small molecule

Target snapshot

BR5402C (BR5402C) — Boryung Pharmaceutical Co., Ltd. BR5402C is a small molecule that targets the HIF-1α pathway.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
BR5402C TARGET	BR5402C	Boryung Pharmaceutical Co., Ltd	phase 2	HIF-1α inhibitor	HIF-1α
ZX-7101A for oral suspension	ZX-7101A for oral suspension	Nanjing Zenshine Pharmaceuticals	phase 3	HIF-1α inhibitor	HIF-1α
WX-0593 Tablets	WX-0593 Tablets	Qilu Pharmaceutical Co., Ltd.	phase 3	HIF-1α inhibitor	HIF-1α
PK101-002	PK101-002	PMG Pharm Co., Ltd	phase 3	HIF-1α inhibitor	HIF-1α

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIF-1α inhibitor class)

1. Boryung Pharmaceutical Co., Ltd · 1 drug in this class
2. Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
3. Nanjing Zenshine Pharmaceuticals · 1 drug in this class
4. PMG Pharm Co., Ltd · 1 drug in this class
5. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class